Adial Pharmaceuticals, Inc. Expected to Post FY2023 Earnings of ($0.49) Per Share (NASDAQ:ADIL)

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Rating) – Equities research analysts at Litchfield Hills Research issued their FY2023 EPS estimates for Adial Pharmaceuticals in a report released on Monday, April 3rd. Litchfield Hills Research analyst T. O’neill anticipates that the company will earn ($0.49) per share for the year. The consensus estimate for Adial Pharmaceuticals’ […]

Related Keywords

Bankolea Johnson , ,Adial Pharmaceuticals Price Performance ,Renaissance Technologies ,Empirical Financial Services ,Millennium Management ,Nasdaq ,Citadel Advisors ,Institutional Trading Of Adial Pharmaceuticals ,Litchfield Hills Research ,Adial Pharmaceuticals ,News Ratings For Adial Pharmaceuticals Daily ,Adial Pharmaceuticals Inc ,Virtu Financial ,Get Rating ,Hills Research ,Adial Pharmaceutical ,Financial Services ,Empirical Wealth Management ,Adial Pharmaceuticals Daily ,Nasdaq Adil ,Cadil ,Medical ,Earnings Estimates ,